Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 7
Submit an article Journal homepage
1,878
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Quality-adjusted survival time without symptoms or toxicity of acalabrutinib with or without obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia

Jeff P. Sharmana Willamette Valley Cancer Institute and Research Center, Eugene, OR, USACorrespondence[email protected]
View further author information
,
Paulo Mirandab AstraZeneca, Gaithersburg, MD, USAView further author information
,
Jack Roosb AstraZeneca, Gaithersburg, MD, USAView further author information
,
Ugochinyere Emeribeb AstraZeneca, Gaithersburg, MD, USAView further author information
,
Ling Caic AstraZeneca, South San Francisco, CA, USAView further author information
,
Bengt Liljasb AstraZeneca, Gaithersburg, MD, USAView further author information
&
Priyanka Gaitondeb AstraZeneca, Gaithersburg, MD, USAView further author information
 show all
Pages 1243-1252 | Received 13 Jan 2023, Accepted 27 Apr 2023, Published online: 23 May 2023

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.